Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT05401214 Approved for marketing - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this pre-approval access is to provide Niraparib plus Abiraterone Acetate (Nira/AA combination) in the treatment of (a) participant(s) with first line metastatic castration-resistant prostate cancer with specific Homologous Recombination Repair (HRR) gene alterations.

NCT ID: NCT04452136 Approved for marketing - Prostate Cancer Clinical Trials

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This study provides expanded access to radiotracer Gallium 68 (68Ga)-prostate-specific membrane antigen (PSMA)-HBED-CC (68Ga-PSMA-11) with Positron Emission Tomography (PET) imaging for participants with intermediate and high risk prostate cancer before prostatectomy or for suspected biochemical recurrence of their prostate cancer. Compared to conventional imaging, 68Ga PSMA-HBED-CC might improve the ability to localize the sites of recurrent or metastatic disease, which helps with surgical and other treatment planning.

NCT ID: NCT04377152 Approved for marketing - Prostate Cancer Clinical Trials

Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol provides eligible participants with investigational 68Ga-PSMA-11 PET imaging to detect and localize prostate cancer for initial and subsequent treatment strategy.

NCT ID: NCT04348682 Approved for marketing - Prostate Cancer Clinical Trials

Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging

Start date: n/a
Phase:
Study type: Expanded Access

To provide expanded access to 68Ga-PSMA-11 PET imaging for eligible participants to detect and localize prostate cancer for initial and subsequent treatment strategy.

NCT ID: NCT02355054 Approved for marketing - Clinical trials for Cancer of the Prostate

Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to provide clinical access to PET/CT and PET/MRI with C-11 choline for evaluation of men with biochemically recurrent prostate cancer while awaiting approval of the Washington University Abbreviated New Drug Application for C-11 choline.

NCT ID: NCT01606982 Approved for marketing - Clinical trials for Metastatic Castration-Resistant Prostate Cancer

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.

NCT ID: NCT01217697 Approved for marketing - Clinical trials for Urogenital Neoplasms

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).